Literature DB >> 18626489

Impact of glycans on T-cell tolerance to glycosylated self-antigens.

Anthony W Purcell1, Ian R van Driel, Paul A Gleeson.   

Abstract

There is now substantial evidence that antigen post-translational modifications are recognized by T cells, and alterations in epitope modification has been linked to a number of autoimmune diseases. An estimated one third of the MHC ligands contain post-translational modification of epitopes. A common post-translational modification of proteins is glycosylation and it is predicted on theoretical grounds that approximately 1-5% of MHC ligands may bear a glycan. From numerous studies over the past 15 years it is clear that glycans can influence T cell responses either by contribution to the structure of the epitope or by influencing the profile of peptide epitopes presented by APCs. The influence of glycans on antigen processing and T cell recognition has particular relevance to the induction of tolerance to self-antigens. Here we discuss the potential impact of glycans on the profile of self-epitopes presented by APCs and the consequence of changes in glycosylation to generate neo self-epitopes resulting in the loss of tolerance and the development of autoimmune diseases. With the recent developments in profiling T cell epitopes, and with strategies for modulating glycosylation in vivo, it is now feasible to directly examine the global influence of glycans on self-tolerance and autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18626489     DOI: 10.1038/icb.2008.48

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  16 in total

1.  The Potential Role of Solvation in Antibody Recognition of the Lewis Y Antigen.

Authors:  Somdutta Saha; Ramachandran Murali; Anastas Pashov; Thomas Kieber-Emmons
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2015-10

Review 2.  Post-translationally modified T cell epitopes: immune recognition and immunotherapy.

Authors:  Jan Petersen; Anthony W Purcell; Jamie Rossjohn
Journal:  J Mol Med (Berl)       Date:  2009-09-08       Impact factor: 4.599

3.  Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small cell lung cancer (START): a randomized, double-blind, phase III trial.

Authors:  Michael DeGregorio; Lin Soe; Michael Wolf
Journal:  J Thorac Dis       Date:  2014-06       Impact factor: 2.895

4.  Identification and Characterization of Complex Glycosylated Peptides Presented by the MHC Class II Processing Pathway in Melanoma.

Authors:  Stacy A Malaker; Michael J Ferracane; Florence R Depontieu; Angela L Zarling; Jeffrey Shabanowitz; Dina L Bai; Suzanne L Topalian; Victor H Engelhard; Donald F Hunt
Journal:  J Proteome Res       Date:  2016-09-13       Impact factor: 4.466

Review 5.  Lipopeptides: a novel antigen repertoire presented by major histocompatibility complex class I molecules.

Authors:  Daisuke Morita; Masahiko Sugita
Journal:  Immunology       Date:  2016-08-10       Impact factor: 7.397

Review 6.  Env Exceptionalism: Why Are HIV-1 Env Glycoproteins Atypical Immunogens?

Authors:  P J Klasse; Gabriel Ozorowski; Rogier W Sanders; John P Moore
Journal:  Cell Host Microbe       Date:  2020-04-08       Impact factor: 21.023

Review 7.  Tecemotide: an antigen-specific cancer immunotherapy.

Authors:  Gregory T Wurz; Chiao-Jung Kao; Michael Wolf; Michael W DeGregorio
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

8.  Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: an exploratory study.

Authors:  Eva Rossmann; Anders Österborg; Eva Löfvenberg; Aniruddha Choudhury; Ulf Forssmann; Anja von Heydebreck; Andreas Schröder; Håkan Mellstedt
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 9.  Breaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity.

Authors:  Sandra M McLachlan; Basil Rapoport
Journal:  Endocr Rev       Date:  2013-12-04       Impact factor: 19.871

10.  Adaptive immune activation: glycosylation does matter.

Authors:  Margreet A Wolfert; Geert-Jan Boons
Journal:  Nat Chem Biol       Date:  2013-12       Impact factor: 15.040

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.